References
- 1. Galik S, Oakhill J, Steinberg G. Adipose tissue as an endocrine organ. Mol Cell Endocrinol. 2010;316(2):129-39.
- 2. Karastegiou K, Mohamed-Ali V. The autocrine and paracrine roles of adipokines. Mol Cell Endocrinol. 2010;318(1-2):69-78.
- 3. Koleva D, Orbetzova M, Atanasova P. Adipose tissue hormones and appetite and body weight regulators in insulin resistance. Folia Med. 2013;55(11):25-32.
- 4. Deng Y, Scherer P. Adipokines as novel biomarkers and regulators of the metabolic syndrome. Ann N Y Acad Sci. 2010;1212:E1-E19. doi: 10.1111/j.1749-6632.2010.05875.x.
- 5. Dogru T, Sonmez A, Tasci I, Bozoglu E. Yilmaz MI, Gene H. at al. Plasma resistin levels in patients with newly diagnosed untreated type 2 diabetes mellitus and impaired glucose tolerance. Diabetes Res Clin Pract. 2007;76 (1):2-7.
- 6. Norata GD, Ongari M, Garlaschelli K, Raselli S, Grigore L, Catapano AL. Plasma resistin levels correlate with determinants of the metabolic syndrome. Eur J Endocrinol. 2007;156(2):279-84.
- 7. Utzschneider K, Carr D, Tong J, Wallace T, Hull R, Zrika S at al. Resistin is not associated with insulin sensitivity or metabolic syndrome in humans. Diabetologia. 2005;48(11):2330-3.
- 8. Fukuhura A, Matsuda M, Nishizawa M. Visfatin: a protein secreted by visceral fat that mimics the effects of insulin. Science. 2005;5708(307):426-30.
- 9. Saddi-Rosa P, Olivera C, Giuffrida F, Reis A. Visfatin, glucose metabolism and vascular disease: a review of evidence. Diabetol Metab Syndr. 2010; 26;2:21. doi: 10.1186/1758-5996-2-21.
- 10. Christov Vl, Gocheva N, Petkova M, Zaharieva S, Tankova Tz, Orbetzova M, et al. A consensus of the Bulgarian Institute Metabolic Syndrome. Nauka Endocrinologia. 2010;2:3-70. (in Bulgarian)
- 11. World Health Organization. Definition and diagnosis of Diabetes Mellitus and intermediate Hyperglycaemia. Report of WHO/IDF Consultation. Geneva, World Health Org. 2006.
- 12. Tota-Maharaj R, Defilippis A, Blumenthal R, Blaha M. A practical approach to the metabolic syndrome: review of current concepts and management. Curr Opin Cardiol. 2010;25(5):502-12.
- 13. Borissova A-M, Kovatcheva R, Shinkov A, Atanassova I, Vukov M, Aslanova N et al. Prevalence and features of the metabolic syndrome in unselected bulgarian population. Endocrinologia. 2007;2:68-77. (in Bulgarian)
- 14. Rayanova G, Ganeva S, Todorova K, Lukanov T, Gecheva S. Disorders of the carbohydrate metabolism in patients with metabolic syndrome. Endocrinologia. 2014;3:139-43. (in Bulgarian)
- 15. De Luis DA, Gonzalez SM, Conde R, Aller R, Izaola O, Primo D. lack of association of serum resistin levels with metabolic syndrome criteria in obese patients. Clin Biochem. 2012;44(16):1280-3.
- 16. Silha V, Kresk M, Skrha J, Sucharda P, Nyomba B, Murphy L. Plasma resistin, adiponectin and leptin levels in lean and obese subjects: correlations with insulin resistance. Eur J Endocrinol. 2003;149(4):331-5.
- 17. Ebtesam DL-S and Shehzad A. Leptin, resistin and visfatin: the missing link between endocrine metabolic disorders and immunity. Eur J Med Res. 2013;18(1):12-29.
- 18. Rabe K, Lehrke M, Parhofer K, Broedi U. Adipokines and insulin resistance, Mol Med. 2008; 14 (11-12): 741-751.
- 19. Tan H, Zhong M, Gomg H, Wang S, Zhang Y, Zhang W. Increased serum visfatin in patients with metabolic syndrome. Clinical Endocrinology. 2008; 6(69):878-884.
- 20. Esteghamati A, Morteza A, Zandieh A, Jafari S, Rezaee M, Nakhjavani M. The value of visfatin in the prediction of metabolic syndrome: a multifactorial analysis. J Cardiovasc Tnansl Res. 2012;5(4):541-6.
- 21. Vasilescu R, Ifrim S, Trigoviste C. Relationship between plasma adipokines, inflammation, insulin resistance and subclinical atherosclerosis in newly diagnosed type 2 diabetes. Journal of Diabetes Mellitus. 2011;1(2):17-25.
- 22. Rasouli N, Kern P. Adipocytokines and metabolic complications of obesity. J Clin Endocrinol Metab. 2008;93(11):S64-S73.